BioSpace News Archive

Pharm Country

Novartis Brolucizumab (RTH258) Demonstrates Superiority Versus Aflibercept in Key Secondary Endpoint Measures of Disease Activity in nAMD, a Leading Cause of Blindness

Results showed non-inferiority in primary endpoint, superiority in key retinal health outcomes, and long-lasting effect in patients with neovascular age-related macular degeneration.

November 10, 2017
·
14 min read
American Academy of Ophthalmology Release: Genetic Treatment for Blindness May Soon be Reality

Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy, according to research presented today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology.

November 10, 2017
·
2 min read
Business

CheckedUp Expands 3D and AI Capabilities Through Licensing Deal

CheckedUp announced that it has licensed 3D imaging technologies from Cirle, a medical technology incubator, for use in its patient engagement platform.

November 10, 2017
·
3 min read
Getinge’s Board of Directors Proposes a Distribution of the Patient Post-Acute Care Business Area to Getinge’s Shareholders

The proposal includes the distribution of all shares in Arjo, where each share of series A in Getinge entitles to one share of series A in Arjo and each share of series B in Getinge entitles to one share of series B in Arjo.

November 10, 2017
·
12 min read
Drug Development

Infinity Pharma Reports IPI-549 Clinical and Translational Data From Completed Monotherapy Dose-Escalation Component of Phase I/Ib Clinical Study in Patients With Advanced Solid Tumors at SITC Annual Meeting

These data from the recently completed monotherapy dose-escalation component of the Phase I/Ib study demonstrated that IPI-549 dosed once daily (QD) was well tolerated and clinically active.

November 10, 2017
·
11 min read
Quotient Sciences Launches as the New Global Identity for Quotient Clinical

Quotient Clinical announces its renaming to Quotient Sciences (Quotient), following the acquisitions of Co-Formulate, QS Pharma and SeaView Research.

November 10, 2017
·
2 min read
Business

U.S. Dept. of Veterans Affairs Renews and Expands Cancer Testing Contract With Personal Genome Diagnostics

The contract includes PDGx’s CancerSELECT 125 tissue and PlasmaSELECT64 liquid biopsy profiling panels.

November 10, 2017
·
2 min read